Synthesis and biological evaluation of cryptophycin analogs with substitution at C-6 (fragment C region)

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 3, 1999, Pages 369-374

  Varie, David L ^a   Shih, Chuan ^a   Hay, David A ^a   Andis, Sherri L ^a   Corbett, Tom H ^b   Gossett, Lynn S ^a   Janisse, Samantha K ^a   Martinelli, Michael J ^a   Moher, Eric D ^a   Schultz, Richard M ^a   Toth, John E ^a  

^a ELI LILLY AND COMPANY   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CRYPTOPHYCIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DIASTEREOISOMER; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LEUKEMIA CELL; REACTION ANALYSIS; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DEPSIPEPTIDES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; PEPTIDES, CYCLIC; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0033535112     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00748-3     Document Type: Article

References (20)

1. Schwartz, R. E.; Hirsch, C. F.; Sesin, D. F.; Flor, J. E.; Chartrain, M.; Fromtling, R. E.; Harris, G. H.; Salvatore, M. J.; Liesch, J. M.; Yudin, K. J. Ind. Microbiol. 1990, 5, 113.
2. (a) Subbaraju, G.V.; Golakoti, T.; Patterson, G. M.; Moore, R. E. J. Nat. Prod. 1997, 60, 302.
3. (b) Trimurtulu, G.; Ohtani, I; Patterson, G. M.; Moore, R. E.; Corbett, T. H.; Valeriote, F. A.; Demchik, L. J. Am. Chem. Soc. 1994, 116, 4729.
4. Barrow, R. A.; Hemscheidt, T.; Liang, J.; Paik, S.; Moore, R. E.; Tius, M. A. J. Am. Chem. Soc. 1995, 117, 2479.
5. (a) de Muys, J-M.; Erg, R.; Nguyen, D.; Go, B.; Fortin, S.; Lavallee, J-F. Bioorg. Med. Chem. Lett. 1996, 6, 1111.
6. (b) Rej, R.; Nguygen, D.; Go, B.; Fortin, S.; Lavallee, J-F. J. Org. Chem. 1996, 61, 6289.
7. (c) Salamonczyk, G. M.; Han, K.; Guo, Z-W.; Sih, C. J. J. Org. Chem. 1996, 61, 6893.
8. (d) Ali, S. M.; Goerg, G. I. Tetrahedron Lett. 1997, 38, 1703.
9. (e) Leahy, J. W.; Gardinier, K. M. J. Org. Chem. 1997, 62, 7098.
10. (f) Shimizu, I.; Furuyama, M. Tetrahedron: Asymmetry 1998, 9, 1351.
11. (a) Worzolla, J. F.; Cao, J.; Ehlhardt, W. J.; Harrison, S. D.; Law, K. L.; Martinelli, M. J.; Self, T. D.; Starling, J. J.; Shih, C.; Theobold, K. S.; Toth, J. E.; Zimmerman, J. L.; Corbett, T. H. Proc. Am. Assoc. Cancer Res. 1997, 38:A1516, 225.
12. (b) Corbett, T.; Valeriote, F.; Simpson, C.; Moore, R.; Tius, M.; Hemscheidt, T.; Liang, J.; Paik, S.; Polin, L.; Pugh, S.; Kushner, J.; Harrison, S.; Shih, C.; Martinelli, M. Proc. Am. Assoc. Cancer Res. 1997, 38:A1515, 225.
13. Golakoti, T.; Ogino, J.; Heltzel, C. E.; Husebo, T. Le; Jensen, C. M.; Larsen, L. K.; Patterson, G. M. L.; Moore, R. E.; Mooberry, S. L.; Corbet, T. H.; Valeriote, F. A. J. Am. Chem. Soc. 1995, 117, 12030.
14. Carlsen, P. H.; Katsuki, T.; Martin, V. S.; Sharpless, K. B. J. Org. Chem. 1981, 46, 3936.
15. The reaction of the imidazolide derived from acids 10 and fragment D (9) required higher temperatures and longer reaction times as the size of the alkyl groups α to the C-5 carbonyl increased. Toluene was used as solvent for the preparation of 10d.
16. Jeffrey, P. D.; McCombie, S. W. J. Org. Chem. 1982, 47, 587.
17. The major by-product of the cyclization reaction was a cyclic dimer. For optimized reaction conditions see: Fray, A. H. Tetrahedron: Asymmetry 1998, 9, 2777.
18. The diastereomeric mixtures of epoxides 15 were isolated in 80-90% yields. The overall yields of chlorohydrins 2 are based on the amount of pure desired diastereomer obtained after chromatography.
19. Schultz, R. M.; Shih C.; Wood, P. G.; Harrison, S. D.; Elhhardt, W. J. Oncology Reports 1998, 5, 1089.
20. Norman, B. H.; Hemscheidt, T.; Schultz, R. M.; Andis, S. L. J. Org. Chem. 1998, 63, 5288.